Menu: Home :: go to Journal :: switch to Russian :: switch to English
You are here: all Journals and Issues→ Journal→ Issue→ Article

STOMACH CANCER: MOLECULAR BIOLOGICAL FEATURES

Annotation

An overview of the literature on the epidemiology, diagnosis and molecular- biological characteristics of gastric cancer is provided. The role of matrix metalloproteinases and their inhibitors in tumor invasion and metastasis, including in stomach cancer is shown. Thus, clinically and experimentally increased expression of matrix metalloproteinases and their activity against type 4 gene in the process of metastasis is demonstrated. The correlation relationship between the increase in the expression of matrix metalloproteinases by tumor cells with progression, metastasis and angiogenesis is proved.

Keywords

stomach cancer; epidemiology; diagnostics; metastasis; matrix metalloproteinases; tumor progression.

Full-text in one file

Download

UDC

616-006

Pages

957-969

References

1. Davydov M.I. Zabolevaemost' zlokachestvennymi novoobrazova-niyami naseleniya Rossii i stran SNG v 2007 g. // Vestnik RONTs im. N.N. Blokhina RAMN. M., 2009. T. 20 (3). S. 52-90. 2. Davydov M.I., Turkin I.N., Davydov M.M. // Entsiklopediya khirur-gii raka zheludka. M., 2011. S. 536. 3. Sasako M.J. What is reasonable treatment for gastric adenocarcinoma? // Gastroenterol. 2000. V. 35. P. 116-120. 4. Davydov M.I., Ter-Ovanesov M.D. Khirurgicheskie aspekty raka zheludka: sovremennye aspekty problemy // 50 lektsiy po khirur-gii / pod red. V.S. Savel'eva // Triada-Kh. 2004. S. 307-331. 5. Pasechnikov V.D., Churkov S.Z. Epidemiologiya raka zheludka // Rossiyskiy zhurnal gastroenterologii, gepatologii, koloprokto-logii. 2002. T. 12 (3). S. 18-26. 6. Crew K.D., Neugut A.I. Epidemiology of upper gastrointestinal malig-nances // Semin Oncol. 2004. V. 31 (4). P. 450-464. 7. Baryshev A.G., Yankin A.V., Skotarev N.P. Otsenka rannikh rezul'-tatov operativnogo lecheniya kardioezofageal'nogo raka // Vestnik RONTs imeni N.N. Blokhina RAMN. 2003. T. 1. S. 80-81. 8. Tyulyandin S.A., Perevodchikova N.I., Nosov D.A. Minimal'nye klinicheskie rekomendatsii Evropeyskogo obshchestva meditsinskoy onkologii (ESMO) // M.: Izdat. gruppa RONTs im. N.N. Blokhina RAMN, 2008. 9. Davydov M.I., Aksel' E.M. Statistika zlokachestvennykh novoob-razovaniy v Rossii i stranakh SNG v 2004 g. // Vestnik RONTs im. N.N. Blokhina. 2006. T. 17 (3). S. 132. 10. Merabishvili V.M. Rak zheludka: epidemiologiya, profilaktika, otsenka effektivnosti lecheniya na populyatsionnom urovne // Prak-ticheskaya onkologiya. 2001. T. (3). S. 2-8. 11. Bondar' V.G., Baker I.D. Sovremennye tendentsii v khirurgii raka zheludka i funktsional'nye rezul'taty khirurgicheskogo lecheniya // Arkhiv klinicheskoy i eksperimental'noy meditsiny. 2004. T. 13 (1-2). S. 112-116. 12. Skoropad V.Yu., Berdov B.A. Retsidivy raka zheludka: zakonomer-nosti razvitiya, profilaktika i lechenie // Rossiyskiy onkologi-cheskiy zhurnal. 2005. T. 6. S. 47-52. 13. Stilidi I.S., Nered S.N., Ryabov A.B. Rak zheludka // Problemy klinicheskoy meditsiny. 2005. T. 4. S. 16-20. 14. Tarasov V.A., Vinogradov M.V., Klechikov V.Z. i dr. Khirurgicheskoe lechenie rasprostranennykh form raka zheludka // Prakticheskaya onkologiya. 2001. T. 3. S. 52-58. 15. Nikulin M.P., Sel'chuk V.Yu. Rak zheludka // Russkiy meditsinskiy zhurnal. 2003. T. 11 (26). S. 1441-1449. 16. Maruyama K., Kaminishi M., Hayashi K. Gastric cancer treated in 1991 in Japan: data analysis of nationwide registry // Gastric cancer. 2006. T. 9. S. 51-66. 17. Khvastunov R.A., Danilov S.P. Rak zheludka: standarty i indivi-dual'nye aspekty taktiki khirurgicheskogo lecheniya // Sovremennaya onkologiya. 2007. T. 9 (1). S. 58-65. 18. Maruyama K. Surgical treatment and end results of gastric cancer. Tokyo: National Cancer Center, 1985. 270 r. 19. Nikulin M.P. Minimal'naya rezidual'naya bolezn' pri rake zhe-ludka // Immunologiya gemopoeza. 2007. T. 4 (2). S. 132-147. 20. Kim J.S., Kim M.A., Kim T.M. et al. Biomarker analysis in stage III-IV (M0) gastric cancer patients who received curative surgery followed by adjuvant 5-fluorouracil and cisplatin chemotherapy: epidermal growth factor receptor (EGFR) associated with favourable survival // British journal of cancer. 2009. V. 100. P. 732-738. 21. Kopnin B.P. Misheni deystviya onkogenov i opukholevykh supresso-rov: klyuch k ponimaniyu bazovykh mekhanizmov kantserogeneza (ob-zor) // Biokhimiya. 2000. T. 65. S. 5-33. 22. Gershteyn E.S., Stilidi I.S., Kushlinskiy N.E., Davydov M.I. Sravnitel'noe immunofermentnoe issledovanie matriksnykh me-talloproteinaz-2, -7, -9 i ikh tkanevogo ingibitora 2 tipa v opu-kholyakh i plazme krovi bol'nykh rakom zheludka // Tekhnologii zhi-vykh sistem. 2013. T. 10 (3). S. 48-52. 23. Ivanov A.A., Gladskikh O.P., Kuznetsova A.V., Danilova T.I. Mezh-kletochnye i kletochno-matriksnye vzaimodeystviya v patologii // Mol. Med. 2005. T. 2. P. 16-20. 24. Rovenskiy Yu.A. Kletochnye i molekulyarnye mekhanizmy opukhole-voy invazii // Biokhimiya. 1998. T. 63 (9). S. 1204-1221. 25. Klisho E.V., Kondakova I.V., Choynzonov E.L. i dr. Prognostiche-skaya znachimost' proteaz u bol'nykh ploskokletochnymi kartsino-mami golovy i shei // Byul. SO RAMN. 2005. T. 2 (116). S. 82-91. 26. Leeman M.F., Curran S., Murray G.I. New insights into the roles of matrix metalloproteinases in colorectal cancer development and pro-gression // J. Pathol. 2003. V. 201 (4). P. 528-534. 27. Heppner K.J., Matrisian L.M., Jensen R.A., Rodgers W.H. Expression of most matrix metalloproteinase family members in breast cancer represents a tumor-induced host response // Am J. Pathol. 1996. V. 149 (1). P. 273-282. 28. Kahari V.M., Johansson N., Grenman R. et al. Expression of collage-nase-3 (MMP-13) by tumor cells in squamous cell carcinomas of the head and neck // Adv. Exp. Med. Biol. 1998. V. 451. P. 63-68. 29. Malemud C.J. Matrix metalloproteinases (MMPs) in health and dis-ease: an overview // Front. Biosci. 2006. V. 11. P. 1696-1701. 30. Gilles C., Bassuk J.A., Pulyaeva H. et al. SPARC/osteonectin induces matrix metalloproteinase 2 activation in human breast cancer cell lines // Cancer Res. 1998. V. 58 (23). P. 5529-5536. 31. Egeblad M., Werb Z. New functions for the matrix metalloproteinases in cancer progression // Nat. Rev. Cancer. 2002. V. 2 (3). P. 161-174 32. Westermarck J., Kahari V.M. Regulation of matrix metalloproteinase expression in tumor invasion // Faseb. J. 1999. V. 13 (8). P. 781-792. 33. Bartsch J.E., Staren E.D., Appert H.E. Matrix metalloproteinase expression in breast cancer // J. Surg. Res. 2003. V. 110 (2). P. 383-392. 34. Johansson N., Vaalamo M., Grenman S. et al. Collagenase-3 (MMP-13) is expressed by tumor cells in invasive vulvar squamous cell carcinomas // Am J. Pathol. 1999. V. 154 (2). P. 469-480. 35. Ahokas K., Lohi J., Illman S.A. et al. Matrix metalloproteinase-21 is expressed epithelially during development and in cancer and is up-regulated by transforming growth factor-beta1 in keratinocytes // Lab. Invest. 2003. V. 83 (12). P. 1887-1899. 36. Sato H., Takino T., Miyamori H. Roles of membrane-type matrix metalloproteinase-1 in tumor invasion and metastasis // Cancer Sci. 2005. V. 96 (4). P. 212-217. 37. Ganusevich I.I. Rol' matriksnykh metalloproteinaz (MMP) pri zlokachestvennykh novoobrazovaniyakh. 1. Kharakteristika MMP re-gulyatsiya ikh aktivnosti, prognosticheskoe znachenie // Onkologiya. 2010. T. 12. № 1. S. 10-16. 38. Visse R., Nagase H. Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry // Circ. Res. 2003. V. 92 (8). P. 827-839. 39. Liotta L.A., Tryggvason K., Garbisa S. et al. Metastatic potential correlates with enzymatic degradation of basement membrane collagen // Nature. 1980. V. 284 (5751). P. 67-68. 40. Deryugina E.I., Quigley J.P. Matrix metalloproteinases and tumor metastasis // Cancer Metastasis Rev. 2006. V. 25 (1). P. 9-34. 41. Nelson A.R., Fingleton B., Rothenberg M.L., Matrisian L.M. Matrix metalloproteinases: biologic activity and clinical implications // J. Clin. Oncol. 2000. V. 18 (5). P. 1135-1149. 42. Agarwal D., Goodison S., Nicholson B. Expression of matrix metallo-proteinase 8 (MMP-8) and tyrosinase-related protein-1 (TYRP-1) cor-relates with the absence of metastasis in an isogenic human breast cancer model // Differentiation. 2003. V. 71 (2). P. 114-125. 43. Ramnath N., Creaven P.J. Matrix metalloproteinase inhibitors // Curr. Oncol. Rep. 2004. V. 6 (2). P. 96-102. 44. Murphy G., Nagase H. Progress in matrix metalloproteinase research // Mol. Aspects Med. 2008. V. 29 (5). P. 290-308. 45. Sounni N.E., Janssen M., Foidart J.M., Noel A. Membrane type-1 matrix metalloproteinase and TIMP-2 in tumor angiogenesis // Matrix Biol. 2003. V. 22 (1). P. 55-61. 46. Brew K., Dinakarpandian D., Nagase H. Tissue inhibitors of metallo-proteinases: evolution, structure and function // Biochim. Biophys. Acta. 2000. V. 1477 (1-2). P. 267-283. 47. Mannello F., Gazzanelli G. Tissue inhibitors of metalloproteinases and programmed cell death: conundrums, controversies and potential implications // Apoptosis. 2001. V. 6 (6). P. 479-482. 48. Kaden J.J., Dempfle C.E., Grobholz R. et al. Interleukin-1 beta pro-motes matrix metalloproteinase expression and cell proliferation in calcific aortic valve stenosis // Atherosclerosis. 2003. V. 170 (2). P. 205-211. 49. Shi J., Schmitt-Talbot E., DiMattia D.A., Dullea R.G. The differential effects of IL-1 and TNF-alpha on proinflammatory cytokine and matrix metalloproteinase expression in human chondrosarcoma cells // Inflamm Res. 2004. V. 53 (8). P. 377-389. 50. Bjorklund M., Heikkila P., Koivunen E. Peptide inhibition of catalytic and noncatalytic activities of matrix metalloproteinase-9 blocks tumor cell migration and invasion // J. Biol. Chem. 2004. V. 279 (28). P. 29589-29597. 51. Fan J., Wang X., Wu L. et al. Macrophage-specific overexpression of human matrix metalloproteinase-12 in transgenic rabbits // Transgenic Res. 2004. V. 13 (3). P. 261-269. 52. Li Z., Ren Y., Wu Q.C. et al. Macrophage migration inhibitory factor enhances neoplastic cell invasion by inducing the expression of matrix metalloproteinase 9 and interleukin-8 in nasopharyngeal carci-noma cell lines // Chin. Med. J. (Engl.). 2004. V. 117 (1). P. 107-114. 53. Owen J.L., Iragavarapu-Charyulu V., Lopez D.M. T cell-derived matrix metalloproteinase-9 in breast cancer: friend or foe? // Breast Dis. 2004. V. 20. P. 145-153. 54. Littlepage L.E., Egeblad M., Werb Z. Coevolution of cancer and stromal cellular responses // Cancer. Cell. 2005. V. 7 (6). P. 499-500. 55. Baker E.A., Leaper D.J. Profiles of matrix metalloproteinases and their tissue inhibitors in intraperitoneal drainage fluid: relationship to wound healing // Wound Repair Regen. 2003. V. 11 (4). P. 268-274. 56. Hidalgo M., Eckhardt S.G. Development of matrix metalloproteinase inhibitors in cancer therapy // J. Natl. Cancer Inst. 2001. V. 93 (3). P. 178-193. 57. Korotkova E.A., Gershteyn E.S., Prorokov V.V., Kushlinskiy N.E. Klinicheskie perspektivy issledovaniya matriksnykh metallopro-teinaz i ikh tkanevykh ingibitorov u bol'nykh rakom tolstoy kishki // Voprosy biologicheskoy meditsinskoy i farmatsevticheskoy khimii. 2012. T. (10). S. 41-46. 58. Duffy M.J. Proteases as prognostic markers in cancer // Clin. Cancer Res. 1996. V. 2 (4). P. 613-618. 59. Deryugina E.I., Quigley J.P. Pleiotropic roles of matrix metalloprotei-nases in tumor angiogenesis: contrasting, overlapping and compensatory functions // Biochim Biophys Acta. 2010. V. 1803 (1). P. 103-120. 60. Brinckerhoff C.E., Rutter J.L., Benbow U. Interstitial collagenases as markers of tumor progression // Clin. Cancer Res. 2000. V. 6 (12). P. 4823-4830. 61. Abraham D., Zins K., Sioud M. et al. Host CD147 blockade by small interfering RNAs suppresses growth of human colon cancer xeno-grafts // Front. Biosci. 2008. V. 13. P. 5571-5579. 62. Behrens P., Mathiak M., Mangold E. et al. Stromal expression of invasion-promoting, matrix-degrading proteases MMP-1 and -9 and the Ets 1 transcription factor in HNPCC carcinomas and sporadic colorectal cancers // Int J. Cancer. 2003. V. 107 (2). P. 183-188. 63. Allgayer H. Molecular regulation of an invasion-related molecule--options for tumour staging and clinical strategies // Eur. J. Cancer. 2006. V. 42 (7). P. 811-819. 64. Bird N.C., Mangnall D., Majeed A.W. Biology of colorectal liver metastases: A-review // J. Surg. Oncol. 2006. V. 94 (1). P. 68-80. 65. Rundhaug J.E. Matrix metalloproteinases and angiogenesis // J. Cell. Mol. Med. 2005. V. 9 (2). P. 267-285. 66. Hendrix M.J.C., Seftor E.A., Hess A.R., Seftor R.E.B. Vasculorgenic mimicry and tumor-cell plasticity // Nature Reviews Cancer. 2003. V. 3. P. 411-422. 67. Ala-aho R., Kahari V.M. Collagenases in cancer // Biochimie. 2005. V. 87 (3-4). P. 273-286. 68. Bonomi P. Matrix metalloproteinases and matrix metalloproteinase inhibitors in lung cancer // Semin. Oncol. 2002. V. 29 (1 Suppl 4). P. 78-86. 69. Herszenyi L., Plebani M., Carraro P. et al. Proteases in ga-strointestinal neoplastic diseases // Clin. Chim. Acta. 2000. V. 291 (2). P. 171-187. 70. Hofmann U.B., Westphal J.R., Van Muijen G.N., Ruiter D.J. Matrix metalloproteinases in human melanoma // J. Invest. Dermatol. 2000. V. 115 (3). P. 337-344. 71. Bisson C., Blacher S., Polette M. et al. Restricted expression of mem-brane type 1-matrix metalloproteinase by myofibroblasts adjacent to human breast cancer cells // Int. J. Cancer. 2003. V. 105 (1). P. 7-13. 72. Bergers G., Brekken R., McMahon G. Matrix metalloproteinase-9 triggers the angiogenic switch during car-cinogenesis // Nature Cell Biology. 2000. V. 2 (10). P. 737-744. 73. Farina A., Tacconelli A., Cappabianca L. et al. Inhibition of human MDA-MB-231 breast cancer cell invasion by matrix metalloproteinase 3 involves degradation of plasminogen // Eur. J. Biochem. 2002. V. 269 (18). P. 4476-4483. 74. Xu Z., Shi H., Li Q. et al. Mouse macrophage metalloelastase generates angiostatin from plasminogen and suppresses tumor angiogenesis in murine colon cancer // Oncol. Rep. 2008. V. 20 (1). P. 81-88. 75. Kirimlioglu H., Kirimlioglu V., Yilmaz S. et al. Role of matrix metalloproteinase-7 in colorectal adenomas // Dig. Dis. Sci. 2006. V. 51 (11). P. 2068-2072. 76. Collins H.M., Morris T.M., Watson S.A. Spectrum of matrix metallo-proteinase expression in primary and metastatic colon cancer: relationship to the tissue inhibitors of metalloproteinases and membrane type-1-matrix metalloproteinase // Br J. Cancer. 2001. V. 84 (12). P. 1664-1670. 77. Baker A.H., Edwards D.R., Murphy G. Metalloproteinase inhibitors: biological actions and therapeutic opportunities // J. Cell. Sci. 2002. V. 115 (Pt. 19). P. 3719-3727. 78. Gershteyn E.S., Korotkova E.A., Prorokov V.V., Kushlinskiy N.E. Klinicheskoe znachenie issledovaniya assotsiirovannykh s opukhol'yu proteaz v opukholyakh i plazme krovi bol'nykh kolorektal'nym rakom // Molekulyarnaya meditsina. 2013. T. 1. S. 49-55. 79. Belizon A., Kirman I., Karten M. et al. Rapid increase in serum levels of matrix metalloproteinase-9 (MMP-9) postoperatively is associated with a decrease in the amount of intracellular MMP-9 // Surg. Innov. 2005. V. 12 (4). P. 333-337. 80. de Hingh I.H., Waas E.T., Lomme R.M. et al. Circulating matrix metal-loproteinase-9 is transiently elevated after colorectal surgery // Int. J. Colorectal Dis. 2004. V. 19 (5). P. 446-450. 81. Kirman I., Jain S., Cekic V. et al. Altered plasma matrix metalloprotei-nase-9/tissue metalloproteinase-1 concentration during the early postoperative period in patients with colorectal cancer // Surg. Endosc. 2006. V. 20 (3). P. 482-486. 82. Nikkola J., Vihinen P., Vuoristo M.S. et al. High serum levels of matrix metalloproteinase-9 and matrix metalloproteinase-1 are asso-ciated with rapid progression in patients with metastatic melanoma // Clin. Cancer. Res. 2005. V. 11 (14). P. 5158-5166. 83. Nakajima M., Welch D.R., Wynn D.M. et al. Serum and plasma M(r) 92,000 progelatinase levels correlate with spontaneous metastasis of rat 13762NF mammary adenocarcinoma // Cancer Res. 1993. V. 53 (23). P. 5802-5807. 84. Jumper C., Cobos E., Lox C. Determination of the serum matrix metal-loproteinase-9 (MMP-9) and tissue inhibitor of matrix metalloprotei-nase-1 (TIMP-1) in patients with either advanced small-cell lung can-cer or non-small-cell lung cancer prior to treatment // Respir. Med. 2004. V. 98 (2). P. 173-177. 85. Frank G.A., Zavalishina L.E., Andreeva Yu.Yu. Sostoyanie vnekle-tochnogo matriksa i markery adgezii v urotelial'nom rake moche-vogo puzyrya // Arkhiv patol. 2005. T. 67 (3). S. 11-14. 86. Cohenuram M., Saif M.W. Epidermal growth factor receptor inhibition strategies in pancreatic cancer: past, present and the future // JOP. 2007. V. 9 (8). P. 4-15. 87. Haitel A., Posch B., El-Baz M. Bilharzial related, organ confined, muscle invasive bladder cancer: prognostic value of apoptosis markers, proliferation markers, p53, E-cadherin, epidermal growth factor receptor and c-erbB-2 // J. Urol. 2001. V. 165 (5). P. 1481-1487. 88. Delektorskaya V.V., Perevoshchikov A.G., Golovkov D.A., Kushlin- skiy N.E. Prognosticheskaya znachimost' ekspressii matriksnykh metalloproteinaz v adenokartsinomakh tolstoy kishki i ikh meta-stazakh // Byulleten' eksperimental'noy biologii i meditsiny. 2007. T. 143 (4). S. 434-438. 89. Abdel-Wahed M.M., Asaad N.Y., Aleskandarany M. Expression of matrix metalloproteinase-2 in renal cell carcinoma // J. Egypt. Natl. Canc. Inst. 2004. V. 16 (3). P. 168-177. 90. Aglund K., Rauvala M., Puistola U. Gelatinases A and B (MMP-2 and MMP-9) in endometrial cancer-MMP-9 correlates to the grade and the stage // Gynecol Oncol. 2004. V. 94 (3). P. 699-704. 91. Kato K., Hara A., Kuno T. Matrix metalloproteinases 2 and 9 in oral squamous cell carcinomas: manifestation and localization of their ac-tivity // J. Cancer Res. Clin. Oncol. 2005. V. 131 (6). P. 340-346. 92. Turpeenniemi-Hujanen T. Gelatinases (MMP-2 and -9) and their natural inhibitors as prognostic indicators in solid cancers // Biochimie. 2005. V. 87 (3-4). P. 287-297. 93. He L., Chu D., Li X. et al. Matrix metalloproteinase-14 is a negative prognostic marker for patients with gastric cancer // Dig. Dis. Sci. 2013. V. 58 (5). P. 1264-1270. 94. Kubben F.J., Sier C.F., Hawinkels L.J. et al. Clinical evidence for a protective role of lipocalin-2 against MMP-9 autodegradation and the impact for gastric cancer // Eur. J. Cancer. 2007. V. 43 (12). P. 1869-1876. 95. Mrena J., Wiksten J.P., Nordling S. et al. MMP-2 but not MMP-9 associated with COX-2 and survival in gastric cancer // J. Clin. Pa-thol. 2006. V. 59 (6). P. 618-623. 96. Zhang L.L.S., Lin J.Y., Lin H. Imbalance between expression of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in invasiveness and metastasis of human gas-tric carcinoma // World J. of Gastroenterology. 2003. V. 9 (5). P. 899-904. 97. Sampieri C.L., de la Pena S., Ochoa-Lara M. et al. Expression of matrix metalloproteinases 2 and 9 in human gastric cancer and superficial gastritis // World J. Gastroenterol. 2010. V. 16 (12). P. 1500-1505. 98. Scartozzi M., Galizia E., Freddari F. Molecular biology of sporadic gastric cancer: prognostic indicators and novel therapeutic approaches // Cancer treatment reviews. 2004. V. 30. P. 451-459. 99. Velverde C., Macarulle T., Casado E. Novel targets in gastric and esophageal cancer // Critical reviews in oncology/hematology. 2006. V. 59. P. 128-138. 100. Wu C.Y., Wu M.S., Chiang E.P. et al. Plasma matrix metalloproteinase-9 level is better than serum matrix metalloproteinase-9 level to predict gastric cancer evolution // Clin. Cancer Res. 2007. V. 13 (7). P. 2054-2060. 101. Wu J.Y., Lu H., Sun Y. et al. Balance between polyoma enhancing activator 3 and activator protein 1 regulates Helicobacter pylori-stimulated matrix metalloproteinase 1 expression // Cancer Res. 2006. V. 66 (10). P. 5111-5120. 102. Yoshikawa T., Tsuburaya A., Kobayashi O. Protein levels of tissue inhibitor of metalloproteinase-1 in tumor extracts as a marker for prognosis and recurrence in patients with gastric can-cer // Gastric cancer. 2006. V. 9. P. 106-113. 103. Fanelli M.F., Chinen L.T., Begnami M.D. et al. The influence of trans-forming growth factor-alpha, cyclooxygenase-2, matrix metalloprotei-nase (MMP)-7, MMP-9 and CXCR4 proteins involved in epithelial-mesenchymal transition on overall survival of patients with gastric cancer // Histopathology. 2012. V. 61 (2). P. 153-161. 104. de Mingo M., Moran A., Sanchez-Pernaute A. et al. Expression of MMP-9 and TIMP-1 as prognostic markers in gastric carcinoma // He-patogastroenterology. 2007. V. 54 (73). P. 315-319. 105. He Q., Chen J., Lin H.L. Expression of peroxisome proliferators-activated receptor γ, E-cadherin and matrix metelloproteinases-2 in gastric carcinoma and lymph node metastases // Chin. Med. J. 2007. V. 120 (17). P. 1498-1504. 106. Zhang Q.W., Liu L., Chen R. et al. Matrix metalloproteinase-9 as a prognostic factor in gastric cancer: a meta-analysis // Asian Pac. J. Cancer Prev. 2012. V. 13 (6). P. 2903-2908. 107. Al-Batran S.E., Pauligk C., Wirtz R. The validation of matrix metallo-proteinase-9 mRNA gene expression as a predictor of outcome in pa-tients with metastatic gastric cancer // Ann Oncol. 2012. V. 23 (7). P. 1699-1705. 108. Chu D., Zhang Z., Li Y. et al. Matrix metalloproteinase-9 is associated with disease-free survival and overall survival in patients with gastric cancer // Int. J. Cancer. 2011. V. 129 (4). P. 887-895. 109. de Mingo M., Moran A., Sanchez-Pernaute A. Expression of MMP-9 and TIMP-1 as prognostic markers in gastric carcinoma // Hepatoga-stroenterology. 2007. V. 54 (73). P. 315-319. 110. Dragutinovic V., Izrael-Zivkovic L., Radovanovic N. Relation of matrix metalloproteinase-9 to different stages of tumors in the serum of gastric cancer // Dig. Dis. Sci. 2009. V. 54 (6). P. 1203-1207. 111. Kubben F.J., Sier C.F., van Duijn W. et al. Matrix metalloproteinase-2 is a consistent prognostic factor in gastric cancer // Br J. Cancer. 2006. V. 94 (7). P. 1035-1040. 112. Wu Z.Y., Li J.H., Zhan W.H., He Y.L. Lymph node micrometastasis and its correlation with MMP-2 expression in gastric carcinoma // World J. of Gastroenterology. 2006. V. 12 (18). P. 2941-2944. 113. He Q., Chen J., Lin H.L. et al. Expression of peroxisome proliferator-activated receptor gamma, E-cadherin and matrix metalloproteinases-2 in gastric carcinoma and lymph node metastases // Chin. Med. J. (Engl.). 2007. V. 120 (17). P. 1498-1504. 114. Ou Y.R., Kang M., Zhou L. [Infection with L-form of Helicobacter pylori and expressions of MIF, MMP9 and VEGF in gastric carcinoma] // Nan. Fang. Yi. Ke. Da. Xue. Xue. Bao. 2014. V. 34 (2). P. 180-187. 115. Fang W.L., Liang W.B., Gao L.B. et al. Genetic polymorphisms in Matrix Metalloproteinases -1 and -7 and susceptibility to gastric can-cer: an association study and meta-analysis // Iran J. Allergy Asthma Immunol. 2013. V. 12 (3). P. 203-210. 116. Yang X., Liu Y., Yang Y., Li B. Update meta-analysis on MMP-7-181A>G polymorphism and cancer risk: evidence from 25 studies // Gene. 2013. V. 521 (2). P. 252-258. 117. Yonemura Y., Endou Y., Fujita H. et al. Role of MMP-7 in the forma-tion of peritoneal dissemination in gastric cancer // Gastric Cancer. 2000. V. 3 (2). P. 63-70. 118. Yoshikawa T., Yanoma S., Tsuburaya A. et al. Expression of MMP-7 and MT1-MMP in peritoneal dissemination of gastric cancer // Hepatogastroenterology. 2006. V. 53 (72). P. 964-967. 119. Koskensalo S., Mrena J., Wiksten J.P. et al. MMP-7 overexpression is an independent prognostic marker in gastric cancer // Tumour Biol. 2010. V. 31 (3). P. 149-155. 120. Zheng J., Chu D., Wang D. et al. Matrix metalloproteinase-12 is asso-ciated with overall survival in Chinese patients with gastric cancer // J. Surg Oncol. 2013. V. 107 (7). P. 746-751. 121. Liu H.Q., Song S., Wang J.H., Zhang S.L. Expression of MMP-3 and TIMP-3 in gastric cancer tissue and its clinical significance // Oncol. Lett. 2011. V. 2 (6). P. 1319-1322. 122. Sampieri C.L., Leon-Cordoba K., Remes-Troche J.M. Matrix metallo-proteinases and their tissue inhibitors in gastric cancer as molecular markers // J. Cancer Res. Ther. 2013. V. 9 (3). P. 356-363. 123. Zhang M., Zhu G.Y., Gao H.Y. et al. Expression of tissue levels of matrix metalloproteinases and tissue inhibitors of metalloproteinases in gastric adenocarcinoma // J. Surg. Oncol. 2011. V. 103 (3). P. 243-247. 124. Shim K.N., Jung S.A., Joo Y.H., Yoo K. Clinical significance of tissue levels of matrix metalloproteinases and tissue inhibitors of metalloproteinases in gastric cancer // J. Gastroenterol. 2007. V. 42 (2). P. 120-128. 125. Kemik O., Kemik A.S., Sumer A. et al. Levels of matrix metalloprotei-nase-1 and tissue inhibitors of metalloproteinase-1 in gastric cancer // World J. Gastroenterol. 2011. V. 17 (16). P. 2109-2112. 126. Kim M., Kim H.J., Choi B.Y. et al. Identification of potential serum biomarkers for gastric cancer by a novel computational method, mul-tiple normal tissues corrected differential analysis // Clin. Chim. Acta. 2012. V. 413 (3-4). P. 428-433. 127. Sawada T., Yashiro M., Sentani K. et al. New molecular staging with G-factor supplements TNM classification in gastric cancer: a multicenter collaborative research by the Japan Society for Gastroenterological Carcinogenesis G-Project committee // Gastric Cancer. 2014. 128. Al-Batran S.E., Werner D. Recent advances and future trends in the targeted therapy of metastatic gastric cancer // Expert Rev. Gastroente-rol Hepatol. 2014. 129. Gencer S., Cebeci A., Irmak-Yazicioglu M.B. Matrix metalloproteinase gene expressions might be oxidative stress targets in gastric cancer cell lines // J. Chin. Cancer Res. 2013. V. 25 (3). P. 322-333. 130. Brand K., Baker A.H., Perez-Canto A. et al. Treatment of colorectal liver metastases by adenoviral transfer of tissue inhibitor of metalloproteinases-2 into the liver tissue // Cancer Res. 2000. V. 60 (20). P. 5723-5730. 131. Celiker M.Y., Wang M., Atsidaftos E. et al. Inhibition of Wilms' tumor growth by intramuscular administration of tissue inhibitor of metalloproteinases-4 plasmid DNA // Oncogene. 2001. V. 20 (32). P. 4337-4343. 132. Vecchione L., Orditura M., Ciardiello F., De Vita F. Novel investiga-tional drugs for gastric cancer // Expert Opin Investig Drugs. 2009. V. 18 (7). P. 945-955.

Received

05.05.2014

Section of issue

Scientific articles

Для корректной работы сайта используйте один из современных браузеров. Например, Firefox 55, Chrome 60 или более новые.